Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, shares insights into the role of CPX-351 in the treatment of acute myeloid leukemia (AML). While this agent has been approved by the FDA and EMA for certain populations, Dr Thol explains that the trials which led to the approval of CPX-351 only included elderly patients. Therefore, randomized data on the safety and efficacy of this agent in a younger population are eagerly awaited. Dr Thol highlights the AMLSG 30-18 trial (NCT03897127), which will evaluate CPX-351 in younger patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Advisory Board for BMS, Novartis, AbbVie, Menarini, Rigel Honorarium: AbbVie, Astellas.